Oaktree Acquisition Corp. III Life Sciences 3/26/2026 Earnings Report

Oaktree Acquisition Corp. III Life Sciences EPS Results

• Actual EPS: $0.08
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Oaktree Acquisition Corp. III Life Sciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Oaktree Acquisition Corp. III Life Sciences Announcement Details

• Date: 3/26/2026
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) (NASDAQ: OACC) is a special purpose acquisition company (“SPAC”) formed to pursue merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combinations with one or more businesses in the life sciences sector. Incorporated as a Cayman Islands exempted company, OACC is sponsored by Oaktree Capital Management, a global alternative investment firm with a longstanding track record in credit strategies and private equity. The SPAC structure provides a pool of cash and public equity to support target companies in biopharmaceuticals, medical devices, diagnostics and other related segments of the life sciences industry.

Since completing its initial public offering in December 2020, OACC has been actively evaluating potential targets worldwide, with a primary focus on North America and Europe. The company’s search criteria emphasize businesses with innovative product pipelines, scalable platforms and strong management teams capable of addressing significant unmet medical needs. OACC’s board and management team draw on Oaktree Capital’s deep industry expertise and global network to assess opportunities, structure transactions and support acquired companies through post-closing integration.

Governance and oversight are provided by a board of directors and executive officers that include senior professionals affiliated with Oaktree Capital Management. Leveraging the sponsor’s rigorous due-diligence framework and operational support, OACC seeks to deliver long-term value for public shareholders by combining financial discipline with strategic guidance tailored to life sciences enterprises. The SPAC format offers target companies a streamlined path to public markets, enhanced visibility and access to growth capital under the oversight of an experienced sponsor.